

Index

Note: Page numbers of article titles are in **boldface** type.

A

Activated clotting time (ACT) test

- for dabigatran, 485
- for ECMO, 659–660
- for new oral anticoagulants, 441
- uses of, 471

Activated factor VII, for anticoagulant reversal, 578–582

Activated partial thromboplastin time (aPTT)

- factors prolonging, 466–469
- for dabigatran, 481, 483, 490–496
- for ECMO, 661–662
- for intracranial bleeding, 590
- for new oral anticoagulants, 441
- for trauma patient, 564
- guidelines for, 466
- predictive value of, 469–472
- uses of, 453–465

Acute coronary syndrome

- apixaban for, 510
- rivaroxaban for, 507

ADOPT (Apixaban Dosing to Optimize Protection from Thrombosis), 510

ADVANCE (Apixaban Dosed Orally Versus Anticoagulation with Injectable Enoxaparin to Prevent Venous Thromboembolism) study, 508

AFASAK trials, 547–549

AFFIRM study, 541

Agratoban, for ECMO, 664–665

Amiodarone, for atrial fibrillation prevention, 540

AMPLIFY (Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-line Therapy), 507, 509, 529, 532

Angiotensin receptor blockers, for atrial fibrillation prevention, 540–541

Angiotensin-converter enzyme inhibitors, for atrial fibrillation prevention, 540–541

Anticoagulation and anticoagulants. *See also specific agents.*

- approved, 444
- bleeding induced by. *See* Bleeding.
- D-dimer concentration and, **675–686**
- for atrial fibrillation. *See* Atrial fibrillation.
- for venous thromboembolism. *See* Venous thromboembolism.
- in pediatric ECMO, **655–673**
- in trauma patients, **563–574**
- intracerebral hemorrhage induced by, **587–594**
- perioperative management of, **637–654**
- pharmacology of, **443–452**

Clin Lab Med 34 (2014) 687–697

[http://dx.doi.org/10.1016/S0272-2712\(14\)00068-7](http://dx.doi.org/10.1016/S0272-2712(14)00068-7)

labmed.theclinics.com

0272-2712/14\$ – see front matter © 2014 Elsevier Inc. All rights reserved.

Anticoagulation (*continued*)

- preprocedural management of, **595–611**

- reversal of, **613–621, 623–635**

- screening for, **453–477**

Anti-factor Xa activity test, 512

- for ECMO, 660

- for intracranial bleeding, 590–591

- for trauma patient, 568

- periprocedural, 597

Antifibrinolytic agents, for ECMO, 666–668

Antiphospholipid antibodies, coagulation test results and, 468

Antiplasmin deficiency, coagulation test results and, 469

Antiplatelet agents

- for atrial fibrillation, 550

- for ECMO, 666–667

- in trauma patient, 569–570

- periprocedural management of, 602

Antithrombin III, in ECMO, 664–666

Apixaban

- advantages of, 444

- approval of, 444, 605

- bleeding due to, 445–448, 589–591

- clinical studies of, 504, 508–510

- for atrial fibrillation, 550–551

- for venous thromboembolism, 528–529, 533

- half-life of, 606

- initiation of, 512–513

- measurement of, 597

- monitoring of, 511–512, 637–654

- periprocedural management of, 605–607, **637–654**

- pharmacology of, 444–445, 508

- reversal of, 448–449, 597, 623, 628–629, 631, 639–641

Apixaban Dosed Orally Versus Anticoagulation with Injectable Enoxaparin to Prevent Venous Thromboembolism (ADVANCE) study, 508

Apixaban Dosing to Optimize Protection from Thrombosis (ADOPT), 510

Apixaban for Prevention of Acute Ischemic and Safety Event (APPRAISE) study, 510

Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) study, 506, 509, 551–552

Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-line Therapy (AMPLIFY), 507, 509, 529, 532

Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES), 508–509

APPRAISE (Apixaban for Prevention of Acute Ischemic and Safety Event) study, 510

ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) study, 506, 509, 551–552

ASPIRE trials, 532

Aspirin

- for atrial fibrillation, 544, 546–547, 549

- for ECMO, 666–667

- for venous thromboembolism, 531–532

- in trauma patient, 569–570

- periprocedural management of, 602–605
- ATLAS-TIMI (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction) study, 507
- ATRIA hemorrhage risk score, 543–546
- Atrial fibrillation
 - apixaban for, 508–509
 - edoxaban for, 510
 - incidence of, 443–444, 538
 - periprocedural anticoagulant management in, 597–601
 - postoperative, **537–561**
 - consequences of, 539–540
 - definition of, 538
 - incidence of, 538
 - prevention of, 540–541
 - risk factors for, 538–539
 - thromboembolism prevention in, 542–554
 - treatment of, 541–542
 - rivaroxaban for, 506
- Australian Therapeutic Goods Administration, bleeding statistics from, 578
- AVERROES (Apixaban Versus Acetylacetic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment), 508–509

B

- BAATAF trial, 548
- BAFTA trial, 549
- Beta-blockers, for atrial fibrillation prevention, 540
- Betrixaban, 504, 511
- Bivalirudin, for ECMO, 664–665
- Bleeding, **575–586**
 - intracranial. *See* Intracranial bleeding.
 - management of, 576–582. *See also individual agents*, reversal of.
 - statistics on, 576–578
 - risk of, assessment of, 543–546
- Blood products transfusions, for ECMO, 668–669
- Brain, bleeding in. *See* Intracranial bleeding.
- Bridging therapy, 598–602, 640

C

- CAFA trial, 548
- Calibrated Automated Thrombogram, 491–496
- CAPRIE (Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events) trial, 602
- Cardioversion, for atrial fibrillation, 541–542
- CHAD score
 - for thromboembolism risk, 542–543
 - periprocedural, 599–601
- Clopidogrel
 - for atrial fibrillation, 550

Clopidogrel (*continued*)

- for ECMO, 666–667

- in trauma patient, 569–570

- periprocedural management of, 602

Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial, 602

Coagulation disorders, coagulation test results and, 467–469

Computed tomography, for trauma patient, 565

D

Dabigatran

- approval of, 444, 605

- bleeding due to, 577–578

- intracranial, 589–591

- risk of, 445–448

- for atrial fibrillation, 551

- for venous thromboembolism, 528, 532–533

- half-life of, 606

- in trauma patient, 566–567

- measurement of, **479–501**

- periprocedural, 597

- plasma-based clotting assays, 480–485

- thrombin generation assays, 490–496

- thromboelastography/rotation thromboelastometry, 486–489

- monitoring of, survey of, 637–654

- periprocedural management of, 605–607, **637–654**

- reversal of, 448–449, 579–582, 597, 623, 625–632, 639–641

Dalteparin, for bridging therapy, 598–601

Danaparoid, for ECMO, 665

D-dimer levels, prognostic value of, **675–686**

Deep venous thrombosis, periprocedural anticoagulant management in, 601–602

Dialysis

- D-dimer levels and, 675–686

- for dabigatran reversal, 580–581

Diet, coagulation test results and, 467

Diluted thrombin time, for new oral anticoagulants, 441, 484–485

Dipyridamole, for ECMO, 667

Direct current cardioversion, for atrial fibrillation, 541–542

Direct factor Xa inhibitors, in trauma patient, 568

Direct thrombin inhibitors

- for ECMO, 664–665

- for trauma patient, 566–568

E

EAFT trials, 547

Ecarin chromogenic assay, for dabigatran, 482

Ecarin clotting time

- for dabigatran, 482–484

- for intracranial bleeding, 590

- for new oral anticoagulants, 441

- for trauma patient, 567
- ECMO. *See* Extracorporeal membrane oxygenation.
- Edoxaban
 - advantages of, 444
 - approval of, 444
 - clinical studies of, 504, 510–511
 - for venous thromboembolism, 528
 - initiation of, 512–513
 - monitoring of, 511–512
 - pharmacology of, 510
 - reversal of, 623, 628–629, 631
- EINSTEIN studies, 506–507, 529, 532
- ELATE trials, 531–532
- Elderly persons
 - anticoagulant safety for, 446–447
 - atrial fibrillation in, 538–539
- Embolectomy, for thromboembolism, 527
- Emergency surgery, anticoagulant management in, 598
- Endothelial dysfunction, in ECMO, 658
- ENGAGE studies, 506, 510
- Enoxaparin
 - for bridging therapy, 598–601
 - pharmacology of, 445
- Epsilon-aminocaproic acid, for ECMO, 667
- Erixaban, clinical studies of, 504
- ESPS trials, 547
- European Society of Anaesthesiology guidelines, 643
- EXPERT study, 511
- EXPLORE-Xa study, 511
- EXTEM assay, 488
- Extracorporeal membrane oxygenation, pediatric, **655–673**
 - anticoagulant monitoring in, 659–663
 - anticoagulants for, 663–666
 - blood products transfusions in, 668–669
 - circuit for, 656–657
 - coagulopathy in, 656–659
 - hemostatic adjuncts in, 666–668
 - indications for, 656
 - platelet activation in, 666
 - usage statistics for, 656

F

- Factor VII
 - deficiency of, coagulation test results and, 468
 - for ECMO, 667–668
 - for thrombin inhibitor reversal, 567
 - for warfarin reversal, 566
- Factor Xa activity, for new oral anticoagulants, 441
- Factor XI deficiency, coagulation test results and, 468
- Factor XIII deficiency, coagulation test results and, 469

FEIBA (Factor VIII Inhibitor Bypassing Activity), for anticoagulant reversal, 579, 629
 FIBTEM assay, for dabigatran, 488
 Fondaparinux, for ECMO, 665
 Fresh frozen plasma
 for ECMO, 668–669
 for warfarin reversal, 566, **613–621**

G

Gaucher disease, coagulation test results and, 468
 Gender differences, D-dimer levels and, 675–686
 Geneva score, for pulmonary embolism, 525
 Grading of Recommendations Assessment, Development and Evaluation system, 644

H

HAS BLEED score, 543–546, 601
 Heart valves, mechanical, anticoagulant therapy for, 602
 Hemophilia, coagulation test results and, 469
 HEMORR₂HAGES score, 543–546
 Heparin
 for bridging therapy, 598–601
 for ECMO, 664–666
 for venous thromboembolism, 519–520, 522–527, 529, 531
 in trauma patient, 568
 reversal of, 568
 with neuraxial anesthesia, 607
 Hip replacement
 apixaban for, 508
 rivaroxaban for, 505–506
 HOKUSAI-VTE, 507, 510–511, 529
 Hyperthermia, coagulation test results in, 467
 Hypothermia, coagulation test results in, 467

I

Inflammation, in ECMO, 657
 Innovance D-dimer assay, 677
 International normalized ratio (INR)
 for dabigatran, 480–481
 for intracranial bleeding, 590
 for new oral anticoagulants, 441
 for trauma patient, 565–566
 guidelines for, 466
 periprocedural, 598
 predictive value of, 471–472
 uses of, 453–465
 International Society of Thrombosis and Haemostasis DIC score, 676
 Intracranial bleeding, **587–594**
 treatment of, 589–592
 warfarin-induced, 577, 614

J

JAST trial, 547

K

Kasabach-Merritt syndrome, coagulation test results and, 468

Kidney function, D-dimer levels and, 675–686

Kininogen deficiency, coagulation test results and, 469

Knee replacement

apixaban for, 508

rivaroxaban for, 505–506

L

LASAF trials, 547

Lepirudin, for ECMO, 664–665

Liquid chromatography with tandem mass spectrometry, for dabigatran, 482–483

Lupus anticoagulant, coagulation test results and, 468

Lupus-like anticoagulant, coagulation test results and, 468

M

MAGELLAN (Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Acutely Ill Medical Patients Comparing Rivaroxaban with Enoxaparin) study, 506–507

Magnesium, for atrial fibrillation prevention, 540–541

Mini-Sentinel database, 578

Monotherapy, for venous thromboembolism, 527

Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Acutely Ill Medical Patients Comparing Rivaroxaban with Enoxaparin (MAGELLAN) study, 506–507

N

Neuraxial anesthesia, anticoagulation with, 607

Neurofibromatosis, coagulation test results and, 468

Noonan syndrome, coagulation test results and, 468

P

Partial thromboplastin time, periprocedural, 597

Passoboy factor deficiency, coagulation test results and, 469

Peak value test, for intracranial bleeding, 590

Pediatric patients, extracorporeal membrane oxygenation in, **655–673**

Periprocedural and perioperative management, of anticoagulants, **595–611**

antiplatelet agents, 602

aspirin, 602–605

in atrial fibrillation, 597–601

in deep venous thrombosis, 601–602

in neuraxial anesthesia, 607

Periprocedural (*continued*)

- in venous thromboembolism, 601–602
 - international survey of, **637–654**
 - laboratory tests for, 596–597
 - new oral, 605–607, **637–654**
 - warfarin, 597–602
 - with mechanical heart valves, 602
- Plasma, fresh frozen. *See* Fresh frozen plasma.
- Plasma-based clotting assays, for dabigatran, 480–485
- Platelet(s)
- dysfunction of, in ECMO, 659
 - transfusion of, for ECMO, 668–669
- Platelet count, for trauma patient, 564, 569–570
- Polyunsaturated fatty acids, for atrial fibrillation prevention, 540–541
- Postoperative atrial fibrillation. *See* Atrial fibrillation, postoperative.
- Prasugrel, periprocedural management of, 605
- Prekallikrein deficiency, coagulation test results and, 469
- PREVENT trial, 531–532
- Protamine sulfate, for heparin reversal, 568
- Prothrombin, deficiency of, coagulation test results and, 468
- Prothrombin complex concentrate, 488
- for anticoagulant reversal, 579–582, 591
 - direct factor Xa inhibitors, 568
 - new oral anticoagulants, 578–582, **623–635**
 - thrombin inhibitors, 567–568
 - warfarin, 566, 578, **613–621**
- for ECMO, 667
- Prothrombin time (PT)
- factors prolonging, 466–469
 - for dabigatran, 490–496
 - for intracranial bleeding, 590
 - for new oral anticoagulants, 441
 - for trauma patient, 564
 - guidelines for, 466
 - periprocedural, 597
 - predictive value of, 469–472
 - uses of, 453–465
- Pulmonary Embolism Severity Index, 523, 525–526

Q

- Quick test, for intracranial bleeding, 590

R

- Racial factors, D-dimer levels and, 675–686
- Radiography, for trauma patient, 565
- Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, 509, 551–552, 581–582, 644
- Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexililate in Patients After Heart Valve Replacement (RE-ALIGN), 446, 552, 605

- Rate control, for atrial fibrillation, 541–542
- RE-ALIGN (Randomized, Phase II Study to Evaluate the Safety and Pharmacokinetics of Oral Dabigatran Etexilate in Patients After Heart Valve Replacement), 446, 552, 605
- RECORD (Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism) studies, 505–506
- RECOVER study, 529
- Red blood cell transfusion, transfusion of, 668–669
- Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism (RECORD) studies, 505–506
- RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial, 509, 551–552, 581–582, 644
- REMEDY trial, 532
- RESONATE trial, 532
- Reversal, of anticoagulants. *See individual agents, reversal of.*
- Rhythm control, for atrial fibrillation, 541–542
- Rivaroxaban
 - advantages of, 444
 - approval of, 444, 605
 - bleeding due to
 - intracranial, 589–591
 - risk of, 445–448
 - clinical studies of, 505–508
 - for atrial fibrillation, 550–551
 - for venous thromboembolism, 528–529, 532–533
 - half-life of, 606
 - in trauma patient, 568
 - initiation of, 512–513
 - monitoring of, 511–512
 - periprocedural, 597
 - survey of, 637–654
 - periprocedural management of, 597, 605–607, **637–654**
 - pharmacology of, 444–445, 504–505
 - reversal of, 448–449, 579, 597, 623, 627–632, 639–641
- ROCKET-AF (Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation) study, 506, 509, 551–552
- Rosenthal syndrome, coagulation test results and, 468
- Rotation thromboelastography (ROTEM)
 - for dabigatran, 486, 488
 - for ECMO, 661, 663
 - for trauma patient, 564–565

S

- Sickle cell disease, coagulation test results and, 468
- SPAF trials, 547–549
- SPINAF trial, 548
- Spinal anesthesia, anticoagulation with, 607
- STA Liatest D-dimer assay, 677
- Statins, for atrial fibrillation prevention, 540
- Substance-specific test system, for intracranial bleeding, 590

Switch therapy, for venous thromboembolism, 527
Synchronized DCC, for atrial fibrillation, 542

T

Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome—Thrombolysis in Myocardial Infarction (ATLAS-TIMI) study, 507

Thrombin

generation of, in ECMO, 657
inhibitors of
for ECMO, 664–665
for trauma patient, 566–568

Thrombin clotting time, in trauma patient, 567

Thrombin generation assays, for dabigatran, 490–496

Thrombin time

for dabigatran, 482–483
for intracranial bleeding, 590
for new oral anticoagulants, 441
periprocedural, 597

Thrombocytopenia, in ECMO, 659

Thromboelastography/rotation thromboelastometry

for dabigatran, 486–489
for ECMO, 661, 663
for trauma patient, 564–565, 568

Thromboembolism. *See also* Venous thromboembolism.

in atrial fibrillation, prevention of, 542–554

Thrombolytic therapy, for thromboembolism, 527

Thrombophilia, tests for, 493–496

Ticagrelor, periprocedural management of, 605

Ticlopidine, periprocedural management of, 605

Tinzaparin, for bridging therapy, 598–601

Tranexamic acid, for ECMO, 667

Trauma patients, anticoagulated, **563–574**

assessment of, 564–565
management of, 565–570

Trough test, for intracranial bleeding, 590

V

Vena cava filters, for venous thromboembolism, 527, 530

Venous thromboembolism

incidence of, 443–444
prevention of
apixaban for, 509–510
edoxaban for, 510–511
rivaroxaban for, 504–508
spectrum of, 519–520
treatment of, **519–536**
dabigatran for, 493–496
extended, 531–532

- in acute-phase, 527–530
 - in chronic phase, 522
 - outpatient, 522–526
 - periprocedural, 601–602
 - phases of, 520–522
- Vitamin K, for warfarin reversal, 614
- Vitamin K antagonists. *See also* Warfarin.
- reversal of, **613–621**

W

Warfarin

- bleeding due to, 445–448, 576–577, 589
 - for atrial fibrillation, 546, 548–554
 - for venous thromboembolism, 527–528, 531–532
 - in trauma patient, 565–566
 - periprocedural management with, 597–602
 - pharmacology of, 445
 - reversal of, 565–566, 578, 597–602, 613–621
- WARFASA trials, 531–532
- Whole blood clotting tests, for dabigatran, 485